Skrobek L, Boegemann M, Hegele A
Aktuelle Urol. 2016 Feb;47(1):27-35. doi: 10.1055/s-0042-102823. Epub 2016 Feb 25.
What new developments in urooncology were discussed at the 2015 annual meetings of ASCO, EAU, DGU and ESMO? This review summarises news relevant to the daily diagnosis and treatment of prostate, bladder and kidney cancer. While study results seem to change paradigms in the treatment of prostate cancer, particularly in metastatic but still hormone-sensitive stages, immunotherapeutic strategies for the treatment of kidney and urothelial cancer are very promising and might expand the systemic therapeutic options in the years to come.
2015年美国临床肿瘤学会（ASCO）、欧洲泌尿外科学会（EAU）、德国泌尿外科学会（DGU）和欧洲肿瘤内科学会（ESMO）年会讨论了泌尿肿瘤学的哪些新进展？本综述总结了与前列腺癌、膀胱癌和肾癌日常诊断及治疗相关的新消息。虽然研究结果似乎正在改变前列腺癌的治疗模式，尤其是在转移性但仍对激素敏感的阶段，但肾癌和尿路上皮癌的免疫治疗策略非常有前景，可能会在未来几年扩大全身治疗选择。
